$BNTX News

BioNTech Evaluates Next Steps as Breast Cancer Drug Shows Limited Patient Benefit

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer

BioNTech (BNTX) Expanded Its Oncology Pipeline, Is It Still 25% Below Fair Value?

BioNTech (BNTX) Reworks Phase 3 Breast Cancer Trial Around New Combination Approach

BioNTech Enters Clinical Trial Collaboration And Supply Agreement With Gilead Sciences To Evaluate Pumitamig In Combination With Sacituzumab Govitecan As First-Line Treatment For Patients With Locally Advanced Or Metastatic PD-L1 Low Or Negative Triple-negative Breast Cancer

BioNTech (BNTX) Stock May Be Fully Valued Despite Fresh Oncology Data Preview

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026

BioNTech To Present New Clinical Data From Its Late-Stage Oncology Pipeline With 16 Abstracts At European Society For Medical Oncology, October 23–27; Key Oral Presentations Will Focus On Clinical Data For Pumitamig Plus Docetaxel In Second-Line Metastatic Non-Small Cell Lung Cancer

Trial Miss Might Change The Case For Investing In BioNTech Stock (BNTX)

Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $132

BioNTech (BNTX) Is Down 7.0% After mRNA Cancer Trial Misses PFS Goal Has The Bull Case Changed?

What Does BioNTech (BNTX) Trial Miss Mean For Its Oncology Pipeline?

BioNTech stock falls after cancer trial misses key endpoint

Why Is BioNTech Stock Falling Tuesday?

BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer

BioNTech Reports AHEAD-MERIT Phase 2/3 Clinical Trial Did Not Meet First Dual Primary Endpoint Of Progression-Free Survival For mRNA Cancer Immunotherapy Candidate BNT113 Plus Pembrolizumab Compared With Pembrolizumab Alone

Why Did BioNTech (BNTX) Move Today?

Is BioNTech (NasdaqGS:BNTX) Overvalued As Sales Face A Reset?

Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $114